Back to FARALLON CAPITAL MANAGEMENT, L.L.C. FARALLON CAPITAL MANAGEMENT, L.L.C.

CRNXCRNX
Showing 8 of 14 quarters

Position history for FARALLON CAPITAL MANAGEMENT, L.L.C.FARALLON CAPITAL MANAGEMENT, L.L.C.'s holdings in CRINETICS PHARMACEUTICALS IN

FARALLON CAPITAL MANAGEMENT, L.L.C. holds 9M shares of CRNX (CRINETICS PHARMACEUTICALS IN), worth $336.4M as of 2026-Q2. The position was increased (+7.8% shares). CRNX represents 1.6% of FARALLON CAPITAL MANAGEMENT, L.L.C.'s portfolio.

Current Value

$336.4M

Current Shares

9M

Total Value Change

+$277M

Total Shares Change

+7.8M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
9M
+7.8%
$336.4M1.6%$37.42
53
2026-Q1
Increased
8.3M
+20.3%
$302.8M1.6%$36.32
58
2025-Q4
Increased
6.9M
+20.2%
$322.7M1.4%$46.55
58
2025-Q3
Increased
5.8M
+24.2%
$240.3M1.0%$41.65
53
2025-Q2
Increased
4.6M
+0.9%
$133.6M0.6%$28.76
43
2025-Q1
Increased
4.6M
+13.0%
$154.5M0.7%$33.54
48
2024-Q4
Increased
4.1M
+250.7%
$208.4M0.9%$51.13
70
2024-Q3
Increased
1.2M
+133.8%
$59.4M0.3%$51.10
57

Other major holders of CRNX: FMR LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used